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Br J Pharmacol. 2019;1–16.Background and Purpose: Vascular endothelial growth factor A (VEGF‐A) is a key
mediator of angiogenesis. A striking feature of the binding of a fluorescent analogue
of VEGF165a to nanoluciferase‐tagged VEGF receptor 2 (VEGFR2) in living cells is
that the BRET signal is not sustained and declines over time. This may be secondary
to receptor internalisation. Here, we have compared the binding of three fluorescent
VEGF‐A isoforms to VEGFR2 in cells and isolated membrane preparations.
Experimental Approach: Ligand‐binding kinetics were monitored in both intact
HEK293T cells and membranes (expressing nanoluciferase‐tagged VEGFR2) using
BRET between tagged receptor and fluorescent analogues of VEGF165a, VEGF165b,
and VEGF121a. VEGFR2 endocytosis in intact cells expressing VEGFR2 was
monitored by following the appearance of fluorescent ligand‐associated receptors
in intracellular endosomes using automated quantitative imaging.
Key Results: Quantitative analysis of the effect of fluorescent VEGF‐A isoforms on
VEGFR2 endocytosis in cells demonstrated that they produce a rapid and potent
translocation of ligand‐bound VEGFR2 into intracellular endosomes. NanoBRET can
be used to monitor the kinetics of the binding of fluorescent VEGF‐A isoforms to
VEGFR2. In isolated membrane preparations, ligand‐binding association curves were
maintained for the duration of the 90‐min experiment. Measurement of the koff at
pH 6.0 in membrane preparations indicated shorter ligand residence times than those
obtained at pH 7.4.
Conclusions and Implications: These studies suggest that rapid VEGF‐A isoform‐
induced receptor endocytosis shortens agonist residence times on the receptor (1/koff)
as VEGFR2 moves from the plasma membrane to the intracellular endosomes.1 | INTRODUCTION
Angiogenesis, the growth of new blood vessels from existing vascular
networks, is an important physiological process that can be- - - - - - - - - - - - - - - - - - - - - - - - - -
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related macular degeneration (Chung & Ferrara, 2011; Peach,
Mignone, et al., 2018). VEGF‐A is a key mediator of both angiogen-
esis and vascular permeability, primarily signalling via its cognate- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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What is already known
• VEGF‐A is a key mediator of angiogenesis.
• The binding of VEGF‐A to VEGFR2 is not sustained in
living cells.
What this study adds
• The power of NanoBRET approaches to study real‐time
ligand‐binding kinetics in membranes and cells.
• Fluorescent VEGF‐A isoforms produced a rapid and
potent translocation of ligand‐bound VEGFR2 into
intracellular endosomes.
• Endocytosis shortens agonist residence times as VEGFR2
moves from the plasma membrane to intracellular
endosomes.
What is the clinical significance
• New insights into the impact of cellular location on the
kinetics of VEGFR2 ligand–receptor interactions.
2 PEACH ET AL.BJPreceptor VEGF receptor 2 (VEGFR2; Alexander et al., 2017; Simons,
Gordon, & Claesson‐Welsh, 2016). VEGF‐A is an anti‐parallel,
disulphide‐linked homodimer that binds across immunoglobulin‐like
domains 2 and 3 of VEGFR2 (Ruch, Skiniotis, Steinmetz, Walz, &
Ballmer‐Hofer, 2007). Ligand binding leads to VEGFR2 dimerisation
and conformational changes that enable the auto‐ and trans‐
phosphorylation of intracellular tyrosine residues. The recruitment
of adaptor proteins to VEGFR2 and subsequent initiation of
signalling cascades then lead to cell proliferation, migration, and vas-
cular permeability (Koch, Tugues, Li, Gualandi, & Claesson‐Welsh,
2011; Simons et al., 2016). VEGFR2 can internalise in the
presence or absence of ligand stimulation (Ewan et al., 2006; Jopling
et al., 2009; Jopling, Howell, Gamper, & Ponnambalam, 2011).
Through both clathrin‐dependent and clathrin‐independent mecha-
nisms (Basagiannis et al., 2016), VEGFR2 first accumulates in
Rab5+/EEA1+ endosomes (Gampel et al., 2006). VEGFR2 can then
recycle back to the plasma membrane via short loop Rab4+
endosomes or long loop Rab11+ endosomes (Jopling et al., 2014),
or receptor ubiquitination can initiate lysosomal degradation (Smith
et al., 2016).
Alternative mRNA splicing of the Vegfa gene leads to a number
of endogenous VEGF‐A isoforms of varying length, such as “proto-
typical” VEGF165a or VEGF121a, as well as variants (e.g., VEGF165b)
that have distinct carboxy‐terminus substitutions of exon 8a for
exon 8b (Peach, Mignone, et al., 2018; Woolard et al., 2004). Addi-
tionally, programmed translational readthrough can lead to VEGF‐
Ax, an isoform containing both exon 8a‐ and 8b‐encoded residues
(Eswarappa et al., 2014). The residues present within each VEGF‐A
isoform determine whether they can interact with other membrane
proteins (e.g., neuropilin 1; Cébe Suarez et al., 2006; Parker, Xu, Li,
& Vander Kooi, 2012; Guo & Vander Kooi, 2015; Peach, Kilpatrick,
et al., 2018) and extracellular matrix components (Krilleke et al.,
2007; Vempati, Popel, & Mac Gabhann, 2014). This causes isoforms
to vary in their bioavailability and signalling outcomes with many iso-
forms acting as partial agonists relative to VEGF165a (Peach,
Mignone, et al., 2018). VEGF‐A isoforms also have distinct expres-
sion profiles in health and disease, such as down‐regulation of
VEGF165b in numerous cancer types (Bates et al., 2002; Pritchard‐
Jones et al., 2007). VEGF‐A/VEGFR2 signalling has been targeted
by a number of clinically approved inhibitors used to treat cancer,
such as receptor TK inhibitors (RTKIs) that target the intracellular
ATP‐binding domain (Ferrara & Adamis, 2016).
The development of fluorescence‐based technologies has
advanced our pharmacological understanding of GPCRs, RTKs, and
other classes of membrane proteins (Stoddart, Kilpatrick, & Hill,
2018; Stoddart, White, Nguyen, Hill, & Pfleger, 2016). For example,
real‐time ligand binding can be quantified in living cells using BRET
(Stoddart et al., 2015; Stoddart et al., 2016). This proximity‐based
assay monitors energy transfer between a receptor tagged on its
N‐terminus with a bright 19‐kDa nanoluciferase (NanoLuc) and a
suitable fluorophore acceptor. We previously developed
fluorescent variants of VEGF165a, VEGF165b, and VEGF121a labelled
at a single site with tetramethylrhodamine (TMR; Kilpatrick et al.,2017; Peach, Kilpatrick, et al., 2018). Despite similar affinities,
VEGF165a‐TMR had distinct binding kinetics at VEGFR2 and its co‐
receptor neuropilin 1 expressed in living HEK293T cells (Peach,
Kilpatrick, et al., 2018). VEGF121a‐TMR and VEGF165b‐TMR were
also shown to bind to VEGFR2 but not to neuropilin 1 using both
NanoBRET and live‐cell fluorescence imaging techniques (Peach,
Kilpatrick, et al., 2018).
A striking feature of the binding of VEGF165a‐TMR to VEGFR2 in
intact living cells is that the BRET signal obtained with higher concen-
trations of the fluorescent probe declines over longer incubation
times, after reaching a peak between 15 and 20 min (Kilpatrick et al.,
2017). One possible explanation is that this is a consequence of recep-
tor internalisation and uncoupling of ligand–receptor complexes
within intracellular endosomes (Kilpatrick et al., 2017). Due to the
complex spatiotemporal dynamics of VEGFR2, kinetic profiles of
ligand binding to VEGFR2 in intact living cells are likely to contain
components that represent the initial ligand‐binding interaction and
also components that reflect receptor endocytosis, whereby the
endosomal environment can impact upon the stability of these
ligand–receptor complexes.
In order to isolate the ligand‐binding profiles of fluorescent
VEGF‐A isoforms to VEGFR2 from the potential influences of
agonist‐induced receptor endocytosis, the present study was under-
taken with VEGF165a‐TMR, VEGF165b‐TMR, and VEGF121a‐TMR to:
(a) investigate the concentration‐dependence and temporal profile
of ligand‐induced VEGFR2 endocytosis, (b) the influence of VEGFR2
phosphorylation on endocytosis and ligand binding, and (c) the
kinetics of the ligand–receptor interactions in isolated membrane
preparations, where the potential for parallel receptor endocytosis
is not present.
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2.1 | Cell culture and materials
HEK293T cells (CCLV Cat# CCLV‐RIE 1018, RRID:CVCL_0063) were
maintained at 37°C/5% CO2 in DMEM (Sigma‐Aldrich, USA)
supplemented with 10% fetal calf serum (FCS; Sigma‐Aldrich, USA).
At 70–80% confluency, cells were passaged using PBS (Lonza,
Switzerland) and trypsin (0.25% w/v in versene; Lonza). Stable cell
lines expressing VEGFR2 were generated using FuGENE HD (Promega
Corporation, USA) at a 3:1 ratio of reagent to cDNA. As described pre-
viously by Peach, Kilpatrick, et al. (2018), N‐terminal NanoLuc‐tagged
VEGFR2 (NM_002253) was cloned into a pFN31K vector encoding
the secretory IL‐6 signal peptide fused to the N‐terminus of
NanoLuc, followed by a GSSGAIA linker before the receptor. Addition-
ally, VEGFR2 was cloned into a pFN21A vector with the IL‐6 signal
peptide followed by a sequence encoding HaloTag and an
EPTTEDLYFQSDNAIA linker at the receptor N‐terminus, as described
in Peach, Kilpatrick, et al. (2018). Fluorescent VEGF165a, VEGF165b,
and VEGF121a were labelled at a single N‐terminal cysteine residue
with TMR using the HaloTag mammalian protein detection and purifi-
cation system (G6795; Promega Corporation, USA) as described previ-
ously (Kilpatrick et al., 2017; Peach, Kilpatrick, et al., 2018).
Fluorescent ligands were characterised in terms of labelling efficiency,
dimerisation, and function as described in Kilpatrick et al. (2017) and
Peach, Kilpatrick, et al. (2018). Binding affinities of fluorescent VEGF
isoforms are approximately an order of magnitude lower than those
of their native counterparts (Peach, Kilpatrick, et al., 2018). Ligands
were stored at −20°C in 2.5 mg·ml−1 protease‐free BSA (Millipore,
USA). Cediranib was purchased from Sequoia Research Products
(Pangbourne, UK), and unlabelled recombinant human VEGF isoforms
were purchased from R&D Systems (Abingdon, UK). Furimazine was
bought from Promega Corporation (Madison, USA), and other tissue
culture reagents were purchased from Sigma‐Aldrich (Gillingham, UK).2.2 | Generation of a tyrosine
phosphorylation‐deficient variant of HaloTag‐VEGFR2
and NanoLuc‐VEGFR2
To generate tyrosine phosphorylation‐deficient (VEGFR2‐TPD)
variants, site‐directed mutagenesis was performed for HaloTag‐
VEGFR2 and NanoLuc‐VEGFR2 using the following forward and
reverse complementary primers for mutations: Y951F (Fwd 5′‐GTCA-
AGGGAAAGACTtCGTTGGAGCAATCCC‐3′; Rev 5′‐GGGATTGCTCC
AACGaAGTCTTTCCCTTGAC‐3′), Y1175F (Fwd 5′‐GCAGGATGGCA
AAGACTtCATTGTTCTTCCGATATC‐3′; Rev 5′‐GATATCGGAAGAAC
AATGaAGTCTTTGCCATCCTGC‐3′), Y1214F (Fwd 5′‐GTGACCCCA
AATTCCATTtTGACAACACAGCAGGAATC‐3′; Rev 5′‐GATTCCTGC
TGTGTTGTCAaAATGGAATTTGGGGTCAC‐3′), and Y1054F (Fwd
5′‐GCTTGGCCCGGGATATTTtTAAAGATCCAGATTATGTC‐3′; Rev
5′‐GACATAATCTGGATCTTTAaAAATATCCCGGGCCAAGC‐3′), and
Y1059F was prepared after the Y1054F mutation had beenincorporated (shown in bold below; Fwd 5′‐GATATTTTTAAAGATCC
AGATTtTGTCAGAAAAGGAGATGCTCGC‐3′; Rev 5′‐GCGAGCATC
TCCTTTTCTGACAaAATCTGGATCTTTAAAAATATC‐3′).
The altered nucleotides are shown in lower case. Mutagenesis was
performed sequentially with the above primers to generate theY951F,
Y1054, Y1059F, Y1175F, and Y1214F tyrosine phosphorylation‐
deficient mutant of VEGFR2 (VEGFR2‐TPD; Figure 4d) using Pfu
DNA polymerase (Promega Corporation, USA), followed by sequenc-
ing of the full plasmid to check for off‐target SNPs. All HEK293T cells
also stably expressed a Firefly luciferase reporter downstream of an
NFAT response element to monitor NFAT‐induced gene transcription
(NFAT‐RE‐luc2P; Promega Corporation, USA), as in Carter, Wheal,
Hill, and Woolard (2015).2.3 | Membrane preparations
HEK293T cells stably expressing wild‐type or tyrosine
phosphorylation‐deficient NanoLuc‐VEGFR2 were grown in
DMEM/10% FCS to 80–90% confluency in 148‐mm2 culture dishes
(Corning, USA). The media was then replaced with PBS, cells were
removed from the dish by scraping and then transferred into a 50‐ml
tube. Cells were centrifuged at 378 × g for 12 min at 4°C, the super-
natant was removed, and the remaining pellet was stored at −80°C.
Thawed pellets resuspended in PBS were homogenised using an elec-
tronic handheld IKA T10 Ultra Turrax homogeniser in 10 × 3 s bursts
at 15,000 rpm. Unbroken cells and nuclei were removed by centrifuga-
tion at 1,500 × g for 20 min (4°C). The supernatant was then centri-
fuged at 41,415 × g for 30 min at 4°C to pellet the remaining
membranes. The pellet was resuspended in 1‐ml PBS, transferred to
a borosilicate glass homogeniser mortar, and homogenised 15 times
using an IKA RW16 overhead stirrer attached to a serrated pestle
(Kartell) at 1,000 rpm. Protein concentration was determined using a
bicinchoninic acid assay (Pierce™ BCA Protein Assay; Thermo Fisher
Scientific), and absorbance was measured using a Dynex Technologies
4.25 platereader. Membrane preparations were stored at −80°C, and
retained their luminescence emissions following addition of furimazine
and their ability to bind VEGF‐TMR for at least 10 months.2.4 | Measuring ligand binding using NanoBRET
For whole‐cell experiments with wild‐type VEGFR2, HEK293T
cells stably expressing full‐length NanoLuc‐VEGFR2 were grown to
70–80% confluency. Cells were seeded in DMEM/10% FCS at
35,000 cells per well on white 96‐well clear bottom plates (Greiner
Bio‐One, 655089) pre‐coated with poly‐D‐lysine (0.01 mg·ml−1 in
PBS). Following a 24‐hr incubation at 37°C/5% CO2, media were
replaced with assay buffer, HEPES buffered saline solution (HeBSS;
10mMHEPES, 10mMglucose, 146mMNaCl, 5mMKCl, 1 mMMgSO4,
2 mM sodium pyruvate, 1.3 mM CaCl2; pH 7.2) containing 0.1% BSA at
pH 7.4. In transient transfection experiments, HEK293T cells were
plated at 12,500 cells per well in white 96‐well clear bottom plates
(37°C, 5% CO2). After 24 hr, cells were transiently transfected with
wild‐type or tyrosine phosphorylation‐deficient NanoLuc‐VEGFR2
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reagent to cDNA with 100‐ng cDNA per well. For assays using
membrane preparations derived from stable cell lines, defrosted
membranes were plated in white 96‐well clear bottom plates at
concentrations ranging from 2.5 to 20 μg per well diluted in
HeBSS/0.1% BSA and then incubated for 30 min at 37°C.
For experiments investigating the influence of membrane concen-
tration on NanoBRET signals, increasing concentrations of membranes
prepared from wild‐type VEGFR2 cells were incubated in the presence
and absence of 5‐nM VEGF165b‐TMR. Following incubation for
60 min in the dark, the NanoLuc substrate furimazine (10 μM) was
added to each well and equilibrated for 5 min to enable NanoLuc‐
mediated furimazine oxidation and resulting bioluminescence emis-
sion. Emissions were recorded using the PHERAstar FS platereader
(BMG Labtech), and BRET ratios were calculated as fluorescence over
luminescence emissions from the second of three cycles.
For kinetic experiments, wells were pretreated with the NanoLuc
substrate, furimazine (10 μM), for 5 min to enable NanoLuc‐mediated
furimazine oxidation and resulting bioluminescence emission. BRET
ratios were then measured per well using the PHERAstar FS
platereader (BMG Labtech) using filters measuring NanoLuc emissions
at 450 nm (30‐nm bandpass) and TMR emissions using a longpass
filter at 550 nm. Following four initial measurements, intact cells
were stimulated with two concentrations of VEGF165b‐TMR or
VEGF121a‐TMR at a concentration around the KD (3 nM) and at
20 nM as a saturating concentration. BRET ratios were then calculated
every 30 s for up to 120 min. In contrast, kinetic experiments in mem-
branes used 10 μg per well of membranes, and five concentrations of
each fluorescent VEGF‐A isoform (1–20 nM) were used to calculate
kinetic binding parameters at wild‐type VEGFR2. To investigate the
influence of VEGFR2 phosphorylation on ligand‐binding kinetics at
NanoLuc‐VEGFR2, corresponding cells or membranes were pre‐
incubated with 1‐μM cediranib (Sequoia Research Products), an RTKI
that targets the intracellular ATP‐binding domain, or 0.01% DMSO in
the HeBSS/0.1% BSA assay buffer for 30 min at 37°C. Alternatively,
kinetics were quantified at tyrosine phosphorylation‐deficient
NanoLuc‐VEGFR2 (VEGFR2‐TPD) membranes prepared from a
stable cell line. Kinetic experiments were then performed with four
concentrations of VEGF165b‐TMR (cediranib experiments) or
VEGF121a‐TMR (VEGFR2‐TPD experiments) for 90 min (3–20 nM).
Emissions were recorded every 30 s for 90 min, using the temperature
control function of the PHERAstar FS platereader to maintain condi-
tions at 37°C.
For saturation and displacement experiments, membrane prepara-
tions were used at 5 μg per well. Increasing concentrations of fluores-
cent VEGF‐A isoforms were added in the presence or absence of a
high concentration of corresponding unlabelled ligand (100 nM,
~100‐fold greater than the estimated KD from Peach, Kilpatrick,
et al., 2018). In displacement experiments, membranes were co‐
stimulated with five fixed concentrations of VEGF165a‐TMR
(0.25−3 nM), VEGF165b‐TMR, or VEGF121a‐TMR (0.5–5 nM) in the
presence of vehicle or increasing concentrations of VEGF‐Ax
(0.03–30 nM; R&D Systems). Following a 60‐min incubation (37°C),10‐μM furimazine was added to each well and equilibrated for
5 min. Emissions were recorded using the PHERAstar FS platereader
(BMG Labtech), and BRET ratios were calculated from the second of
three cycles.
Both kinetic and saturation experiments were repeated in wild‐
type NanoLuc‐VEGFR2 membranes to investigate the effect of pH
on ligand binding, using VEGF165b‐TMR as a representative fluores-
cent VEGF‐A isoform. The pH of the assay buffer, HeBSS/0.1% BSA
(pH 7.4), was lowered to 5.8–6.2 with concentrated hydrochloric acid
on the day of the experiment and measured using a pH Meter PB‐11
(Sartorius, Germany). Although EPES buffer has a pKa suited to phys-
iological pH (6.8–8.2), control experiments confirmed the assay buffer
remained within 0.2 of the initial pH in conditions replicating the
experimental set‐up (50 μl at 37°C for 2 hr).2.5 | High‐content widefield imaging quantifying
endocytosis of fluorescent VEGF‐A isoforms
HEK293T cells stably expressing HaloTag‐VEGFR2, NanoLuc‐VEGFR2
(Kilpatrick et al., 2017), or wild‐type HEK293T cells were seeded at
25,000 cells per well in DMEM/10% FCS on black 96‐well clear bot-
tom plates (Greiner Bio‐One, 655090) pre‐coated with poly‐D‐lysine
(0.01 mg·ml−1 in PBS). Following an incubation for 24 hr at 37°C/5%
CO2, media were replaced with assay buffer (serum‐free
DMEM/0.1% BSA). To compare untransfected HEK293T cells with
cells expressing HaloTag‐VEGFR2, cells were stimulated with 10‐nM
VEGF165b‐TMR and VEGF121a‐TMR for 60 min (37°C). All other
widefield imaging assays used cells expressing NanoLuc‐VEGFR2.
For concentration–response experiments, increasing concentrations
of VEGF165a‐TMR, VEGF165b‐TMR, or VEGF121a‐TMR (0.1–100 nM)
were added in duplicate wells (60 min; 37°C/5% CO2). Alternatively,
cells were stimulated with 10‐nM VEGF165a‐TMR, VEGF165b‐TMR,
or VEGF121a‐TMR for between 5 and 120 min as a retrospective
timecourse. Cells were washed with PBS (100 μl per well) and fixed
with 3% paraformaldehyde in PBS for 15 min at room temperature
(RT). Following another PBS wash, nuclei were stained with 2 mg·ml−1
H33342 in PBS for 15 min at RT and then washed and stored in PBS
at 4°C. The following day, cells were imaged using an ImageXpress
Micro widefield high‐content platereader (Molecular Devices, USA).
Plates were imaged at four sites per well using a 20× ELWD (extra
long working distance) objective, with a TRITC filter to image
VEGFxxxx‐TMR (560‐nm excitation, 607‐ to 634‐nm emission, and
2,000‐ms exposure time) and a DAPI filter for nuclei (405‐nm excita-
tion, 447‐ to 460‐nm emission, and 25‐ms exposure time). Images
were analysed using a granularity algorithm (Molecular Devices),
whereby nuclei were identified based upon their size (5‐ to 25‐μm
diameter) and pixel depth in grey levels, which was kept consistent
between experimental replicates. A nuclear mask defining cell nuclei
was then placed over the nuclei within the acquired image forming
the basis for automated image segmentation. Fluorescent granules
were defined based upon size (2‐ to 15‐μm diameter) and pixel
depth in grey levels. Granules were then assigned to specific nuclei
based upon proximity using the aforementioned segmented image.
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HEK293T cells stably expressing wild‐type or tyrosine
phosphorylation‐deficient HaloTag‐VEGFR2 were seeded at 300,000
cells per well onto poly‐D‐lysine‐coated coverslips (18 × 18 mm,
1.5H; Zeiss, Germany) in six‐well plates. Following a 24 hr incubation
at 37°C/5% CO2, coverslips were transferred to humidified wells
of a six‐well plate lined with parafilm and maintained in PBS to
retain moisture. Receptors were labelled with 0.5‐μM membrane‐
impermeant HaloTag‐Alexa Fluor 647 (Promega Corporation, USA) in
assay buffer (serum free DMEM containing 0.1% BSA). Following
30 min at 37°C/5% CO2, coverslips were washed twice with assay
buffer and then incubated with 10‐nM VEGF121a‐TMR for 5 or
60 min (37°C/5% CO2). Cells were washed with PBS and fixed with
3% paraformaldehyde in PBS for 20 min at RT. Following numerous
wash steps in PBS (3 × 5 min), cells were permeabilised with Triton
X‐100 (0.025% in PBS). To minimise non‐specific antibody labelling,
cells were washed (3 × 5‐min PBS), incubated with 3% BSA/1% gly-
cine (30 min, RT), washed (3 × 5‐min PBS), and blocked with 10% chick
serum in PBS (30 min, RT). This was replaced with the primary mono-
clonal antibody against Rab5 raised in rabbit (IgG; Cell Signaling Tech-
nology Cat# 3547, RRID:AB_2300649) diluted 1:200 in 10% chick
serum and incubated overnight at 4°C. Cells were then washed in
PBS (3 × 5 min) and incubated with the secondary antibody, chick
anti‐rabbit Alexa Fluor 488 (IgG; heavy and light chains; Cat# A‐
21441; ThermoFisher; RRID:AB_2535859) 1:1000 dilution in 10%
chick serum (1 hr, RT). To determine non‐specific immunofluorescent
labelling, this was repeated using a secondary antibody only in the
absence of the primary antibody. Cells were then washed (3 × 5‐min
PBS), and nuclei were stained with 2 mg·ml−1 H33342 in PBS
(15 min, RT) and washed (2 × 5‐min PBS) before coverslips were
mounted onto slides using ProLong Diamond (Thermo Fisher Scien-
tific) and sealed for storage at 4°C. Coverslips were imaged using a
Confocal Zeiss LSM880 fitted with a 63× Pan Apochromat oil objec-
tive (1.4 numerical aperture) using a 1‐μm slice. Wavelengths were
imaged in separate tracks with Rab5 immunolabelling imaged with an
Argon488 laser (491‐ to 571‐nm bandpass; 3% power); VEGF121a‐
TMR was imaged with a DPSS 561‐10 laser (571–615 nm, 3% power);
and HaloTag‐Alexa Fluor 647 was imaged using a HeNe633 laser
(638–747 nm; 15% power). Images were obtained at 1,024 × 1,024
pixels with eight averages and similar gains per replicate. The
immuno‐related procedures used comply with the recommendations
made by the British Journal of Pharmacology.
2.7 | NFAT luciferase reporter gene assay
HEK293T cells stably expressing wild‐type or tyrosine
phosphorylation‐deficient HaloTag‐VEGFR2, as well as NFAT‐RE‐
luc2P, were grown to 70–80% confluency. Cells were seeded at
25,000 cells per well in white 96‐well plates pre‐coated with poly‐D‐
lysine. Following 24 hr at 37%/5% CO2, cell culture media were
replaced with serum‐free DMEM for another 24 hr. Cells were then
stimulated with increasing concentrations of VEGF165a (R&D Systems)
or vehicle (serum‐free DMEM/0.1% BSA). Following stimulation for5 hr at 37%/5% CO2, media were replaced with 50 μl per well assay
buffer and 50 μl per well ONE‐Glo Luciferase reagent (Promega
Corporation, USA). Cells were incubated for 5 min to allow luciferase
to react with the added reagent and for the background luminescence
to subside, and then luminescence emissions were measured using a
TopCount platereader (PerkinElmer, UK). Data were normalised to
their respective vehicle (0%) and response of wild‐type HaloTag‐
VEGFR2 to 10‐nM VEGF165a (100%) per experiment. Data were
pooled from five independent experiments with duplicate wells.
2.8 | Data and statistical analysis
Data were analysed using GraphPad Prism 7.02 (RRID:SCR_002798;
San Diego, CA, USA). Data are presented as mean ± SEM. The data
and statistical analysis comply with the recommendations of the British
Journal of Pharmacology on experimental design and analysis in
pharmacology.
Representative confocal images were processed using ImageJ
(Version 1.52f; RRID:SCR_003070). For colocalisation analysis, images
were corrected to the background fluorescence intensity from each
experimental replicate determined using the non‐specific secondary
antibody only (Rab5, 488 nm) or untransfected cells in each field of
view (TMR, 546 nm; HaloTag‐VEGFR2, 647 nm). The mean back-
ground intensity was calculated for each experimental replicate
(n = 5) and subtracted from each image for manual thresholding. To
quantify colocalization, regions of interest were drawn around each
cell expressing HaloTag‐VEGFR2 using the nuclei stain and phase con-
trast image. Following subtraction of the region outside the region of
interest, colocalisation was determined using pixel‐based measures
between Rab5/TMR and Rab5/HaloTag using the ImageJ plugin
Coloc 2. Images with saturated pixels were excluded from analyses.
Mander's overlap coefficients measure co‐occurance as the proportion
of Rab5 pixels (green) overlapping with VEGF‐TMR (yellow) or
HaloTag‐VEGFR2 (red). These were calculated on a per cell basis, with
a total number of 64 cells (5‐min stimulation) and 68 cells (60‐min
stimulation) pooled from five independent experiments.
Saturation binding curves were fitted simultaneously for total
(fluorescent VEGF‐A ligand alone) and non‐specific binding (obtained
in the presence of 100 nM of unlabelled VEGF‐A) using the equation:
Total binding ¼ Bmax × B½ 
B½  þ KD þM × B½  þ C;
where Bmax is the maximal specific binding, [B] the concentration of
fluorescent ligand (nM), KD the equilibrium dissociation constant
(nM), M the slope of the non‐specific binding component, and C the
y‐axis intercept. Background and non‐specific binding parameters
were shared across all data sets.
Binding affinities (Ki) of the unlabelled ligands were calculated





6 PEACH ET AL.BJPwhere [L] is the concentration of fluorescent ligand used (nM). KD
values (nM) were derived from saturation binding curves. IC50 is the
molar ligand concentration that will inhibit 50% of the specific binding
of the fluorescent ligand concentration [L] and was calculated using
the equation:
%specific VEGF binding ¼ 100 × IC50
A½  þ IC50 ;
where [A] is the concentration of competing drug used.
Fluorescent ligand‐binding association kinetic data were fitted to
the following mono‐exponential association function:
Y ¼ Ymax · 1 − e−kobs · t
 
;
where Ymax equals the level of specific binding at infinite time, t is the
time of incubation, and kobs is the rate constant for the observed rate
of association.
kon and koff values were determined by simultaneously fitting
ligand‐binding association kinetic curves obtained at different fluores-
cent ligand concentrations (L) to the above equation with the follow-






Residence time was calculated as the reciprocal of koff. Kinetically
determined KD values were calculated from these kinetic parameters
using the following equation:
KD ¼ koffkon :
For VEGF165a‐TMR concentration–response curves for
internalisation of ligand–VEGFR2 complexes, themean granule number
per cell was calculated from four images per well. Data are expressed as
a percentage of the responses obtained using 100‐nM VEGF165a‐TMR
(100%) or vehicle (0%). Data were fitted using non‐linear least squares
regression using GraphPad Prism with the following equation:
Response ¼ Emax × B½ 
B½  þ EC50;
where Emax is the maximal response and EC50 is the concentration of
agonist required to produce 50% of the maximum response.
The kinetic data for receptor internalisation were fitted to the
following mono‐exponential association function:
Y ¼ Ymax: 1 − e−kobs :t
 
;
where Ymax equals the level of receptor internalisation at infinite time,
t is the time of incubation, and kobs is the rate constant for the
observed rate of receptor internalisation.
Statistical analyses of differences between Mander's overlap coef-
ficients obtained at 5 and 60 min were performed using an unpaired
non‐parametric Mann–Whitney test. Statistical analysis of thedifference of theMander's overlap coefficient obtained from zero were
performed using a Wilcoxon signed‐rank test. Statistical analysis of
differences between fitted kinetic ligand‐binding parameters, in the
presence and absence of cediranib, was performed using a paired t test.
AUC analysis (GraphPad Prism 7.02) was used to determine the effect
of cediranib on NanoBRET ligand‐binding times courses (Figure 4), and
the statistical significance of these changes was determined by two‐
way ANOVA. Differences between kinetic binding constants in cells
and membranes were performed using one‐way ANOVA with post
hoc Tukey test. Statistical significance was taken as P < .05. A power
calculation was performed to confirm sample number for statistical
comparisons between binding parameters determined by NanoBRET.
This was done on the basis of five separate experiments with the antic-
ipated SD obtained in similar experiments and a calculation of the
statistical power to detect a significant change in a particular parameter
of 0.3 log units. This yielded a power of 0.99; that is, there was a 99%
chance of detecting a significant change in value of 0.3 log units.2.9 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in http://www.guidetopharmacology.org, the
common portal for data from the IUPHAR/BPS Guide to PHARMA-
COLOGY (Harding et al., 2018), and are permanently archived in the
Concise Guide to PHARMACOLOGY 2017/18 (Alexander, Fabbro
et al., 2017; Alexander, Kelly et al., 2017).3 | RESULTS
3.1 | Binding kinetics of VEGF165b and VEGF121a in
intact living HEK293 cells
Initial kinetic studies with VEGF165b‐TMR and VEGF121a‐TMR reca-
pitulated the previous findings obtained with VEGF165a‐TMR in intact
living cells (Kilpatrick et al., 2017). Thus, with concentrations chosen to
be close to their respective KD values (3 nM), the specific binding of
each ligand increased rapidly and was then relatively well maintained
over the course of the experiment (Figure 1a,b). The specific binding
observed with 20‐nM VEGF165b‐TMR or VEGF121a‐TMR, however,
peaked at ~20 min and then declined substantially towards baseline
over the next 70 min (Figure 1a,b).3.2 | Agonist‐mediated internalisation of VEGFR2 in
HEK293T cells
We have previously suggested that the fall in the VEGFR2‐associated
NanoBRET signal observed with VEGF165a‐TMR over longer incuba-
tions periods is a consequence of VEGFR2 internalisation and the dis-
sociation of VEGF165a‐TMR from its receptor within intracellular
endosomes (Kilpatrick et al., 2017). To look into the timecourse and
potency of receptor internalisation by each fluorescent VEGF‐A iso-
form, we investigated receptor endocytosis by monitoring the
FIGURE 1 Long‐term NanoBRET binding profiles of fluorescent VEGF‐A variants at NanoLuc‐tagged VEGFR2 expressed in intact living cells. (a)
Time course of VEGF165b‐TMR and (b) VEGF121a‐TMR binding to full‐length N‐terminal NanoLuc‐VEGFR2 stably expressed in HEK293T cells.
Following 5 min pretreatment with NanoLuc substrate furimazine, ligand was added (x = 0) at both a saturating (20 nM) concentration of
fluorescent ligand and a concentration that was approximately equal to its KD value (3 nM). BRET ratios were calculated every 30 s at 37°C using
the PHERAstar FS platereader. Data were baseline corrected to vehicle to adjust for background emissions. Data are shown as mean ± SEM from
five independent experiments with duplicate wells
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endosomes using unbiased, automated quantitative high‐content
imaging. A granularity algorithm was used to detect the presence
of fluorescent VEGF‐A isoforms within granules of a particular size
(i.e. between 2 and 15 μm; Figure 2a). We have previously shown that
this analysis correlates with the endocytosis of tagged receptors
(Kilpatrick et al., 2017). Minimal VEGF‐TMR containing granules were
detected in untransfected HEK293T cells compared with cells stably
expressing HaloTag‐VEGFR2 (Figure 2b). All three fluorescent VEGF‐
A isoforms stimulated a potent internalisation of VEGFR2 (Figure 2c
and Table 1). In the presence of 10 nM of VEGF165a‐TMR,
VEGF165b‐TMR, or VEGF121a‐TMR, the appearance of ligand‐bound
VEGFR2 in endosomes was rapid with a t1/2 of between 15 and
20 min (Figure 2d and Table 1).3.3 | Presence of VEGF‐TMR and VEGFR2 in Rab5+
endosomes
Immunofluorescent labelling of Rab5 in fixed cells was used to confirm
whether VEGF‐TMR and VEGFR2 complexes were localised in early
Rab5‐positive endosomes, using confocal microscopy for enhanced
axial resolution (z) compared with high‐content widefield imaging in
Figure 2. As a representative VEGF‐TMR ligand, 10‐nM VEGF121a‐
TMR was significantly colocalised with Rab5 (P < .05; Wilcoxon
signed‐rank test; Figure 3a,b) at both intracellular sites and regions
of the plasma membrane by 5 min, whereas it was largely intracellular
by 60 min (Figure 3a,b). This was accompanied by increased
colocalisation with Rab5 at 60 min (Figure 3b; P < .05; Mann–Whitney
test, n = 64 cells and n = 68 cells for 5‐ and 60‐min stimulation, respec-
tively). HaloTag‐VEGFR2 labelled with a membrane‐impermeable dye
was significantly (P < .05) colocalised with Rab5 at 5 min (Figure 3a,c).
At 60 min, there was a small decrease in colocalisation of Rab5 with
HaloTag‐VEGFR2 compared with 5 min (Figure 3c; Mann–Whitneytest, P < .05; n = 64 for 5 min and n = 68 for 60 min), which is consistent
with some recycling of VEGFR2 back to the plasma membrane previ-
ously observed by Kilpatrick et al. (2017).3.4 | Influence of VEGFR2 phosphorylation on ligand
binding in intact cells
Addition of the RTKI cediranib (1 μM), pre‐incubated for 30 min, pro-
duced a significant elevation in the NanoBRET signal at both 5‐ and
20‐nM VEGF165b‐TMR relative to the DMSO control (Figure 4a–c;
P < .05, two‐way ANOVA of every time point, n = 5). This elevation
was similar to that reported previously with an endpoint NanoBRET
binding timecourse for VEGF165a‐TMR (Kilpatrick et al., 2017). How-
ever, as also noted by Kilpatrick et al. (2017), the binding profile of
20‐nM VEGF165b‐TMR continued to decline in the presence of
cediranib following the peak at 20 min when monitored continuously
using real‐time NanoBRET measurements (Figure 4c).
To explore the influence of receptor phosphorylation further, we
generated a tyrosine phosphorylation‐deficient VEGFR2 (VEGFR2‐
TPD) where key intracellular phosphotyrosine residues were mutated
to phenylalanine (Y951F, Y1054F, Y1059F, Y1175F, and Y1214F;
Figure 4d). Receptors were labelled with membrane‐impermeant
HaloTag‐Alexa Fluor 647, and this confirmed the plasma membrane
expression of this VEGFR2 variant (Figure 4e). However,
VEGF121a‐TMR and VEGFR2‐TPD were also localised to intracellular
Rab5+ sites following a 60‐min incubation. Using the same cell line
as those for imaging experiments, the tyrosine phosphorylation‐
deficient VEGFR2 was unable to signal through NFAT in response
to increasing concentrations of VEGF165a in comparison with wild‐
type VEGFR2 (pEC50 = 9.92 ± 0.12; Figure 4f). In intact cells, there
was a significant elevation (P < .05) in NanoBRET signal with both 3‐
and 20‐nM VEGF121a‐TMR (Figure 4g,h; n = 8). It was notable that
there was also a decline in the NanoBRET signal in VEGFR2‐TPD
FIGURE 2 Quantifying endocytosis of VEGF165a‐TMR, VEGF165b‐TMR, and VEGF121a‐TMR ligand–receptor complexes using high‐content
imaging. (a) HEK293T cells expressing NanoLuc‐VEGFR2 were stimulated with 10‐nM fluorescent VEGF165a‐TMR (60 min, 37°C). Cells were
fixed and incubated with nuclear stain (H33342). The following day, cells were imaged with an ImageXpress Micro widefield platereader (20×
ELWD objective; four sites per well) using filter settings for TRITC (left; VEGF165a‐TMR) and DAPI (middle; nuclei). Images were analysed using a
granularity algorithm (Molecular Devices) whereby nuclei stained with H33342 (blue, middle panel) were identified based upon their size (5‐ to
25‐μm diameter) and pixel depth in grey levels. A nuclear mask defining cell nuclei was then placed over the nuclei within the acquired image (right
panel; green spots), forming the basis for automated image segmentation. Fluorescent granules detected in the TRITC channel (right; white spots)
were defined based upon size (2‐ to 15‐μm diameter) and pixel depth in grey levels. Granules were then assigned to specific nuclei based upon
proximity using the aforementioned segmented image. Scale bars represent 20 μm. (b) To confirm receptor specificity, non‐transfected wild‐type
HEK293T cells or stably expressing HaloTag‐VEGFR2 cells were stimulated with 10‐nM VEGF165a‐TMR (n = 5), VEGF165b‐TMR (n = 5), or
VEGF121a‐TMR (n = 5) for 60 min (37°C). Cells were fixed, stained, and imaged, as in (a). Data were normalised to mean vehicle (0%) or VEGF121a‐
TMR stimulation (100%) in HaloTag‐VEGFR2 cells per experiment. (c) Cells were stimulated with increasing concentrations of fluorescent VEGF‐A
variants (60 min, 37°C). Data were normalised to mean vehicle (0%) and 100‐nM VEGF165a‐TMR‐stimulated response (100%) per experiment.
Cells were fixed, stained, and imaged as above. (d) Timecourse of internalisation of VEGF‐TMR complexes, whereby NanoLuc‐VEGFR2 cells were
stimulated with 10‐nM VEGF165a‐TMR, VEGF165b‐TMR, or VEGF121a‐TMR for 0–120 min at 37°C. Cells were fixed, stained, and imaged as above
and then normalised to vehicle (0%) and 60‐min VEGF165a‐TMR stimulation (100%) per experiment. Data from (b–d) are expressed as mean ± SEM
and pooled from five independent experiments unless stated otherwise with duplicate wells imaged at four sites per well
TABLE 1 Concentration–response parameters and kobs values for
fluorescent VEGF‐A‐induced VEGFR2 internalisation in HEK293T
cells expressing NanoLuc‐VEGFR2 derived from experiments similar





VEGF165a‐TMR 7.95 ± 0.09 0.04 ± 0.01 17.5 ± 1.87
VEGF165b‐TMR 7.54 ± 0.08 0.04 ± 0.01 19.8 ± 3.53
VEGF121a‐TMR 7.81 ± 0.12 0.05 ± 0.01 14.8 ± 2.11
Note. Data are mean ± SEM from five separate experiments.
8 PEACH ET AL.BJPafter the initial peak at 20 min. Both wild‐type and tyrosine
phosphorylation‐deficient NanoLuc‐VEGFR2 receptors were
expressed at the same level, as determined by the NanoLuc lumines-
cence emissions (data not shown).3.5 | NanoBRET ligand binding in membrane
preparations
To determine the influence of membrane concentrations on
NanoBRET ligand binding in membranes prepared from NanoLuc‐
FIGURE 3 Localisation of VEGFR2 and VEGF121a‐TMR in Rab5+ endosomes. (a) HEK293T cells expressing HaloTag‐VEGFR2 were labelled with
membrane‐impermeant HaloTag‐Alexa Fluor 647 (red) and stimulated with 10‐nM VEGF121a‐TMR (yellow) for 5 or 60 min at 37°C. Cells were
fixed and permeabilised using Triton X‐100 (0.025% in PBS), and endosomal compartments were labelled with a primary monoclonal Rab5
antibody and secondary chick anti‐rabbit Alexa Fluor 488 antibody (green). Coverslips were imaged using a Zeiss LSM880 (63× oil objective), with
representative images obtained on the same day. Scale bar represents 20 μm. (b, c) Colocalisation parameters were quantified based on regions of
interest drawn around cells positive for HaloTag‐VEGFR2 expression using ImageJ software for Coloc 2 analysis. The Mander's overlap coefficient
represents the proportion of Rab5 (green) colocalised with (b) ligand (VEGF121a‐TMR; yellow) or (c) receptor (HaloTag‐VEGFR2; red), following
stimulation for 5 or 60 min. All coefficient values were pooled from five independent experiments, with a total of 68 cells (5‐min stimulation) or 64
cells (60‐min stimulation). Coefficients obtained at 5 and 60 min were compared using an unpaired Mann–Whitney test (*P < .05; n = 68 or n = 64).
Coefficients were tested for a significant difference (*P < .05) from zero using a Wilcoxon signed‐rank test
PEACH ET AL. 9BJPVEGFR2‐expressing HEK293T cells, we initially investigated the bind-
ing of 5‐nM VEGF165b‐TMR to VEGFR2 over a range of membrane
concentrations (2.5‐ to 20‐μg protein per well). NanoBRET binding
was well maintained across the full range of protein concentrations
(Figure 5a). Membrane concentration was also linearly related to
NanoLuc luminescence (Figure 5b).
The binding of different concentrations of fluorescent VEGF‐A
isoforms monitored by NanoBRET showed clear saturable specific
binding in each case. The KD values obtained in membrane prepara-
tions from these equilibrium binding experiments were slightly
more potent (0.31 ± 0.06, 5.55 ± 0.47, and 2.58 ± 0.34 nM
for VEGF165a‐TMR, VEGF165b‐TMR, and VEGF121a‐TMR, respec-
tively; n = 5 in each case) than those similarly determined in intact
cells (2.03, 9.53, and 5.54 nM; Peach, Kilpatrick, et al., 2018).
However, non‐specific binding was low in all cases (Figure 6a–c).
Competition binding experiments were also conducted for each
fluorescent VEGF‐A isoform with VEGF‐Ax yielding similar pKi
values for the non‐fluorescent ligand (10.18 ± 0.04 [n = 5],
9.96 ± 0.2 [n = 6], and 10.34 ± 0.08 [n = 5]; using VEGF165a‐
TMR, VEGF165b‐TMR, and VEGF121a‐TMR as the fluorescent probe,
respectively; Figure 6d–f).3.6 | Kinetics of the binding of fluorescent VEGF‐A
isoforms to VEGFR2 in membrane preparations
To determine the kinetic constants (kon and koff) for the binding of
fluorescent VEGF‐A isoforms to VEGFR2, we investigated the
timecourse of the binding of five concentrations of VEGF165a‐TMR,
VEGF165b‐TMR, and VEGF121a‐TMR at NanoLuc‐VEGFR2 in
membrane preparations (1–20 nM; Figure 7a–c). Binding of all three
fluorescent VEGF‐A isoforms produced classic ligand‐binding associa-
tion curves that, in contrast to the studies in intact cells (Figure 1),
were maintained for the duration of the experiment (90 min;
Figure 7a–c). Kinetic kon and koff values determined from these
experiments in Table 2 were similar to those previously reported for
these three ligands in intact cells, where the kinetic analysis was
limited to the first 20 min of agonist stimulation (Peach, Kilpatrick,
et al., 2018).
Membrane kinetic experiments were also repeated in the pres-
ence of the RTKI cediranib (Table 3). There was a significant
decrease in koff in membrane preparations when compared with cells
(Table 3), but the koff values were not altered by cediranib treat-
ment. There was a small significant decrease in the kon value for
FIGURE 4 VEGFR2 phosphorylation is not required for the decline in NanoBRET signal. (a) Schematic representing the mechanism of cediranib
at the intracellular ATP‐binding site of VEGFR2. (b, c) HEK293T cells stably expressing NanoLuc‐VEGFR2 were pretreated with 0.01% DMSO
(control) or 1‐μM cediranib (30 min, 37°C). After the addition of furimazine for 5 min, the real‐time binding of (b) 5‐ or (c) 20‐nM VEGF165b‐TMR
was monitored every 30 s for 90 min at 37°C. Data are shown as mean ± SEM from five independent experiments with duplicate wells. AUC
analysis provided the following areas (mean ± SEM): (b) 0.71 ± 0.01 and 0.77 ± 0.01* and (c) 1.80 ± 0.02 and 2.04 ± 0.02* for control and
cediranib‐treated cells respectively. *P < .05 significant difference between control and cediranib‐treated cells (two‐way ANOVA of every time
point). (d) Schematic of tyrosine mutations in the tyrosine phosphorylation‐deficient VEGFR2‐TPD. (e) HEK293T cells stably expressing HaloTag‐
VEGFR2‐TPD were labelled with membrane‐impermeant HaloTag‐Alexa Fluor AF647 and stimulated with 10‐nM VEGF121a‐TMR (60 min, 37°C).
Following cell fixation and permeabilization, Rab5‐positive endosomes were labelled with a monoclonal rabbit antibody and secondary chick anti‐
rabbit Alexa Fluor 488. Cells were imaged using a Zeiss LSM880F Confocal (63× oil objective) with representative images from five independent
experiments. Scale bars show 20 μm. (f) NFAT luciferase production in response to 5‐hr stimulation with increasing concentrations of VEGF165a.
Stable cell lines were then used for Rab5+ confocal imaging figures to confirm cell surface expression. Data are shown as mean ± SEM from five
independent experiments in duplicate wells, expressed as a percentage of response per experiment to 10‐nM VEGF165a at wild‐type HaloTag‐
VEGFR2 (100%) or respective vehicle (0%). (g, h) Time course of VEGF121a‐TMR binding to tyrosine phosphorylation‐deficient NanoLuc‐VEGFR2
expressed transiently in HEK293T cells. Cells were pretreated with furimazine for 5 min, and then (g) 3‐ or (h) 20‐nM ligand was added (x = 0).
BRET ratios were monitored every 30 s at 37°C and baseline corrected to vehicle. Data are expressed as mean ± SEM from eight independent
experiments with duplicate wells. AUC analysis provided the following areas (mean ± SEM): (g) 2.61 ± 0.06 and 3.54 ± 0.07* and (h) 7.28 ± 0.10
and 9.79 ± 0.11*, for wild‐type VEGFR2 and VEGFR2‐TPD cells respectively. *P < .05 significant difference between VEGFR2 and VEGFR2‐TPD
cells (two‐way ANOVA of every time point)
10 PEACH ET AL.BJPVEGF165b‐TMR obtained in intact cells in the presence of cediranib
compared with the DMSO control. The value obtained in the pres-
ence of cediranib was also similar to the kon values obtained inmembranes (Table 3). To quantify the kinetics of binding at the tyro-
sine phosphorylation‐deficient NanoLuc‐VEGFR2 using membrane
preparations, a stable cell line was generated. Kinetic parameters of
FIGURE 5 Influence of membrane concentration on ligand binding between NanoLuc‐tagged receptors and fluorescent VEGF165b‐TMR
detected using NanoBRET. (a) Increasing concentrations of membranes prepared from HEK293T cells expressing NanoLuc‐VEGFR2 were
incubated with vehicle or 5‐nM VEGF165b‐TMR. Following 60‐min incubation at 37°C, BRET ratios were calculated and expressed as mean ± SEM.
Data were pooled from five independent experiments using separate membrane preparations per experiment. (b) Variation in NanoLuc
luminescence detected at different membrane concentrations in a single representative experiment with duplicate wells
FIGURE 6 Binding characteristics of fluorescent VEGF‐A isoforms at NanoLuc‐tagged receptors in membrane preparations. Membrane
preparations from HEK293T cells expressing wild‐type NanoLuc‐VEGFR2 (5 μg per well) were incubated with increasing concentrations of (a)
VEGF165a‐TMR, (b) VEGF165b‐TMR, and (c) VEGF121a‐TMR (60 min, 37°C). Non‐specific binding was determined using 100‐nM unlabelled
VEGFxxxx counterpart (R&D Systems) added simultaneously with fluorescent ligand. Raw BRET ratios are expressed as mean ± SEM from five
independent experiments. Displacement of unlabelled VEGF‐Ax by (d) VEGF165a‐TMR (n = 5), (e) VEGF165b‐TMR (n = 6), or (f) VEGF121a‐TMR
(n = 5) in NanoLuc‐VEGFR2 membrane preparations. Increasing concentrations of unlabelled ligand were added simultaneously with five fixed
concentrations of fluorescent ligand and incubated for 60 min at 37°C. Values are mean ± SEM from five to six independent experiments with
duplicate wells. Bars show the binding obtained with vehicle (white) or fluorescent ligand alone (left to right; highest to lowest concentration of
each fluorescent ligand used)
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to control VEGF121a‐TMR kinetic parameters derived in wild‐type
VEGFR2 membranes (Tables 2 and 3).Taking advantage of our binding assay in membrane preparations,
we investigated the effect of an acidic pH on ligand–receptor binding
to reflect early endosomes (pH 6.0) compared with physiological
FIGURE 7 Binding kinetics of VEGF165a‐TMR, VEGF165b‐TMR, and VEGF121a‐TMR in membrane preparations quantified using NanoBRET.
Membranes (10 μg per well) prepared from NanoLuc‐VEGFR2‐expressing HEK293T cells were pretreated with furimazine to equilibrate for
5 min before addition of five concentrations of (a) VEGF165a‐TMR, (b) VEGF165b‐TMR, and (c) VEGF121a‐TMR (1–20 nM). Measurements were
taken every 30 s for 90 min at 37°C and baseline corrected to vehicle. Data represent mean ± SEM from five independent experiments with
duplicate wells. Individual curves were fit with a simple exponential association model. (d) Saturation binding of VEGF165b‐TMR at NanoLuc‐
VEGFR2 in membrane preparations (5 μg per well), comparing assay buffer at pH 7.4 and 6.0 (HEPES buffered saline solution containing 0.1%
BSA). Membranes were incubated with increasing concentrations of VEGF165b‐TMR for 60 min at 37°C, in the presence and absence of 100‐nM
VEGF165b (R&D Systems) to determine non‐specific binding. Raw BRET ratios are expressed as mean ± SEM from six independent experiments
with duplicate wells. Kinetics of (e) 5‐ and (f) 20‐nM VEGF165b‐TMR at NanoLuc‐VEGFR2 in membrane preparations (10 μg per well), comparing
assay buffer at pH 7.4 and pH 6.0 (HEPES buffered saline solution/0.1% BSA). The binding profile for single VEGF165b‐TMR concentrations are
shown for clarity; however, experiments were performed with four concentrations (3–20 nM) to fit a global kinetic association model, as above.
Data represent mean ± SEM from six independent experiments with duplicate wells
TABLE 2 Kinetic binding parameters of ligand binding to NanoLuc‐VEGFR2 in isolated membranes and intact cells
Ligand
















VEGF165a‐TMR 1.27 × 10
7 ± 0.24 × 107 0.030 ± 0.001 2.21 ± 0.40 33.3 1.54 × 107 0.06 6.64 16.7
VEGF165b‐TMR 3.69 × 10
6 ± 0.67 × 106 0.029 ± 0.002 9.21 ± 2.53 34.5 7.29 × 106 0.06 11.3 16.7
VEGF121a‐TMR 5.13 × 10
6 ± 0.48 × 106 0.019 ± 0.002 3.85 ± 0.61 52.6 8.51 × 106 0.05 5.54 20.0
Note. Values in membrane preparations are mean ± SEM (n = 5) derived from experiments shown in Figure 7 using five concentrations of fluorescent ligand.
Values in intact cells are taken from Peach, Kilpatrick, et al. (2018). KD values shown are the kinetically derived values (koff/kon).
12 PEACH ET AL.BJPextracellular pH (7.4, as above). Using VEGF165b‐TMR as a representa-
tive ligand at membranes expressing wild‐type NanoLuc‐VEGFR2,
there was comparable saturable binding with low non‐specific binding
(Figure 7d). Equilibrium binding constants for VEGF165b‐TMR were
similar at neutral and acidic pH (pH 7.4, KD = 5.29 ± 1.12 nM, and
pH 6.0, KD = 4.43 ± 1.25 nM; n = 6 in both experiments). Kinetic exper-
iments showed similar association binding of VEGF165b‐TMR at both
pH conditions (Figure 7e,f; n = 6). Kinetic parameters derived using four
concentrations of VEGF165b‐TMR show kinetics at an acidic pH had
faster association and dissociation rate constants (Table 3). The KDaffinity estimated from kinetic parameters (koff/kon) also yielded a sim-
ilar binding affinity at both pH conditions, despite the difference in res-
idence times.4 | DISCUSSION
Initial kinetic studies of the ligand binding of VEGF165b‐TMR and
VEGF121a‐TMR, in intact HEK293T cells, recapitulated previous find-
ings obtained with VEGF165a‐TMR in intact living cells (Kilpatrick
TABLE 3 Effect of cediranib and tyrosine phosphorylation deficiency on the binding kinetics of VEGF165b‐TMR to NanoLuc‐VEGFR2




time (min) Kinetic KD (nM)
VEGFR2 WT cellsa VEGF165b‐TMR (5) 0.01% DMSO 4.26 × 10
6 ± 0.50 × 106 0.081 ± 0.009 12.3 19.8 ± 2.96
1‐μM cediranib 2.63 × 106 ± 0.51 × 106* 0.091 ± 0.015 11.0 43.6 ± 14.5
VEGFR2 WT
membranesb
VEGF165b‐TMR (5) 0.01% DMSO 2.69 × 10
6 ± 0.30 × 106* 0.023 ± 0.003* 43.5 9.68 ± 2.70
1‐μM cediranib 2.74 × 106 ± 0.28 × 106* 0.021 ± 0.002* 47.6 8.00 ± 1.52
VEGFR2‐TPD
membranesb
VEGF121a‐TMR (5) None 6.21 × 10
6 ± 1.61 × 106 0.037 ± 0.006 27.0 6.85 ± 1.81
VEGFR2 WT
membranesb
VEGF165b‐TMR (6) pH 7.4 2.34 × 10
6 ± 0.19 × 106 0.023 ± 0.002 43.5 10.2 ± 1.20
pH 6.0 4.39 × 106 ± 0.39 × 106# 0.059 ± 0.019# 17.0 13.3 ± 3.55
Note. Values shown are mean ± SEM, with the number of independent experiments in parentheses. Data were taken from kinetic binding experiments at
wild‐type NanoLuc‐VEGFR2 (VEGFR2 WT) in cells or membranes, or tyrosine phosphorylation‐deficient NanoLuc‐VEGFR2 (VEGFR2‐TPD) membranes.
aKinetic parameters were determined by a global association kinetic fit to four concentrations of fluorescent ligand from initial 20 min in intact cells.
bKinetic parameters were determined by a global association kinetic fit to four concentrations of fluorescent ligand from 90 min in membrane preparations.
*P < .05 for comparison with the kon and koff values determined in 0.01% DMSO in VEGFR2 WT cells (one‐way ANOVA with post hoc Tukey test) com-
pared with DMSO control in VEGFR2 WT cells.
#P < .05; Wilcoxon matched‐pairs signed‐rank test (pH 7.4 vs. pH 6.0). Matched analysis of paired kinetic constants for 0.01% DMSO versus cediranib in
either cells or membranes was not significant.
PEACH ET AL. 13BJPet al., 2017). We have previously reported all three fluorescent VEGF‐
A isoforms bind with nanomolar affinity to VEGFR2 (Kilpatrick et al.,
2017; Peach, Kilpatrick, et al., 2018). Thus, at concentrations close
to their respective KD values, the specific binding of each ligand (mon-
itored by NanoBRET) increased rapidly and was then relatively well
maintained over the course of the experiment. In contrast, specific
binding observed with higher concentrations (e.g., 20 nM) of
VEGF165b‐TMR or VEGF121a‐TMR peaked at ~20 min and then
declined substantially towards baseline over the next 70 min. Previous
studies with VEGF165a‐TMR alone suggested that this was a conse-
quence of VEGFR2 endocytosis and the dissociation of the fluores-
cent ligand from the receptor within intracellular endosomes,
followed by subsequent recycling of ligand‐free VEGFR2 back to the
plasma membrane (Kilpatrick et al., 2017). Published studies in primary
endothelial cells using immunofluorescence antibody labelling or bio-
chemical techniques agreed that VEGFR2 internalised within
30–60 min of VEGF‐A stimulation (Bruns et al., 2010; Ewan et al.,
2006; Jopling et al., 2009).
To determine the agonist potency (EC50 values) and kinetic pro-
file of agonist‐induced VEGFR2 endocytosis, we monitored the
appearance of fluorescent ligand‐associated receptors in intracellular
endosomes using high‐content quantitative imaging. This approach
was able to quantify the internalisation of VEGF‐A ligand isoforms
independently of the known constitutive endocytosis of VEGFR2
(Basagiannis et al., 2016; Ewan et al., 2006; Jopling et al., 2009;
Jopling et al., 2011). All three fluorescent VEGF‐A isoforms stimu-
lated comparable internalisation of VEGFR2 (EC50 = 12–30 nM), with
10 nM of each fluorescent ligand eliciting a rapid appearance of
ligand‐bound VEGFR2 in endosomes (t1/2 of between 15 and
20 min). This contrasted with previous findings in HUVEC that
VEGF121a was less able to induce VEGFR2 endocytosis compared
with VEGF165a (Fearnley et al., 2016). However, it is notable that
the HEK293T cells used in the present study have minimalexpression of the co‐receptor neuropilin 1 (Peach, Kilpatrick, et al.,
2018), whereas human umbilical vein endothelial cells also express
the co‐receptor neuropilin 1. Neuropilin 1 does not interact with
VEGF121a (Peach, Kilpatrick, et al., 2018) but has been reported to
modulate VEGFR2 trafficking (Ballmer‐Hofer, Andersson, Ratcliffe,
& Berger, 2011). We were, however, able to confirm using confocal
microscopy that both VEGF121a‐TMR and VEGFR2 were colocalised
with Rab5 in intracellular endosomes following addition of the fluo-
rescent ligand.
The data obtained from the internalisation assays also indicate that
significant internalisation only occurs at the highest concentrations of
fluorescent VEGF‐A isoforms used (EC50 = 12, 14, and 30 nM for
VEGF165a‐TMR, VEGF121a‐TMR, and VEGF165b‐TMR, respectively).
Interestingly, these values are greater than the corresponding
kinetically derived KD ligand‐binding values determined in membrane
preparations (2.4, 3.9, and 9.2 nM). This might suggest that the binding
affinity of VEGFR2 for VEGF‐A isoforms is lower after receptor activa-
tion as a result of autophosphorylation and engagement with signal-
ling proteins involved in endocytosis. To investigate the impact of
receptor TK activation on this process, we have investigated the effect
of pretreating cells with the RTKI cediranib (Carter et al., 2015).
Cediranib (1 μM) produced no significant effect on the kinetic rate
constants (kon and koff) or KD value of VEGF165b‐TMR determined
from binding to VEGFR2 in HEK293T cell membranes. In intact cells,
however, cediranib produced a small elevation in the NanoBRET signal
similar to that reported previously for VEGF165a‐TMR (Kilpatrick et al.,
2017). This was accompanied by a small decrease in kon but no signif-
icant difference in koff. The combination of these two effects was a
small increase in KD (Table 3). It is also worth emphasising, however,
that very small changes in kinetic parameters may also be a conse-
quence of the need to fit association curves for four or more concen-
trations of fluorescent ligand simultaneously with shared values for kon
and koff.
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generated a tyrosine phosphorylation‐deficient VEGFR2 (VEGFR2‐
TPD) where key intracellular phosphotyrosine residues were mutated
to phenylalanine (Y951F, Y1054F, Y1059F, Y1175F, and Y1214F;
Figure 4d). This mutant form of VEGFR2 was unable to stimulate
NFAT signalling but mimicked the effect of cediranib on VEGF‐TMR
binding and produced a significant increase in the amplitude of the
NanoBRET binding signal obtained with 20‐nM VEGF121a‐TMR. This
is likely to be due to interference with endocytosis pathways that
are dependent on agonist‐induced VEGFR2 activation and phosphory-
lation. However, what is clear from both the experiments with
VEGFR2‐TPD and cediranib is that additional pathways can mediate
VEGFR2 endocytosis. For example, endocytosis of both VEGFR2‐
TPD and VEGF121a‐TMRwas still observed using confocal microscopy
(Figure 4).
Our data suggest that substantial agonist‐induced VEGFR2 endo-
cytosis is occurring in intact HEK293T cells over the concentration
range (1–20 nM) and timecourse (20 min) used previously to assess
ligand‐binding kinetics in live cells (Kilpatrick et al., 2017; Peach,
Kilpatrick, et al., 2018). Furthermore, this internalisation could not be
prevented by interfering with agonist‐induced VEGFR2 phosphoryla-
tion. To investigate the impact that agonist‐induced endocytosis (or
association with other signalling complexes and ancillary proteins in
living cells) may have on the estimation of kinetic ligand‐binding
parameters deduced by NanoBRET in intact cells, we established an
isolated membrane ligand‐binding assay where the potential for paral-
lel agonist‐induced receptor endocytosis and engagement with cyto-
plasmic signalling complexes would be disrupted. NanoBRET ligand
binding with all three fluorescent VEGF‐A isoforms demonstrated
clear specific binding in isolated membrane preparations. Non‐specific
binding, determined in the presence of a high concentration of non‐
fluorescent VEGF‐A ligand, was low over the full concentration range
of fluorescent ligand employed. The equilibrium KD values determined
following a 1‐hr incubation were slightly more potent than those
previously reported in intact cells (Table 2; Kilpatrick et al., 2017;
Peach, Kilpatrick, et al., 2018). This was particularly the case for
VEGF165a‐TMR. Similarly, VEGF‐Ax produced competitive inhibition
of the binding of each fluorescent VEGF‐A isoform in membrane prep-
arations. However, in marked contrast to equivalent studies in intact
living cells, the kinetics of the binding of five different concentrations
of VEGF165a‐TMR, VEGF165b‐TMR, or VEGF121a‐TMR produced
classic ligand‐binding association curves that were maintained for
the duration of the 90‐min experiment.
The kon and koff values determined in membrane preparations were
of a similar order to those previously reported for these three fluores-
cent ligands in intact cells when the kinetic analysis was restricted to
the first 20 min of agonist stimulation, in order to reduce the influence
of receptor endocytosis (Peach, Kilpatrick, et al., 2018). kon rate con-
stants were slightly smaller (1.2‐fold to 2.0‐fold) in membranes than
the corresponding values obtained in intact cells. However, koff rate
constants were approximately fourfold lower (Table 2) than those
determined in HEK293T cells, indicative of a slower agonist dissocia-
tion rate. In matched experiments (Figure 6 and Table 3), thesedifferences were significant (P < .05). These data suggest that the
impact of agonist‐induced VEGFR2 endocytosis on kinetically derived
kon, koff, and KD values is not large if the analysis in cells is restricted to
early time points. However, the process of receptor endocytosis does
lead to an underestimation of the equilibrium off‐rate kinetic constant
and receptor residence time (1/koff) of VEGF165b‐TMR on the recep-
tor at the plasma membrane (e.g. the calculated residence time in cells
for VEGF165b‐TMR was 12.3 min whilst that in membranes prepara-
tions was 43.5 min; Table 3). This is consistent with our earlier
suggestion that rapid dissociation of VEGF165a‐TMR from VEGFR2
occurs in the environment of intracellular endosomes (as a conse-
quence of the lower pH or the presence of endosomal proteases)
and allows rapid recycling of ligand‐free VEGFR2 back to the cell
surface (Kilpatrick et al., 2017). Interestingly, in the tyrosine
phosphorylation‐deficient VEGFR2‐TPD, the kinetic constants deter-
mined in membranes for VEGF121a‐TMR were within a factor of two
of those derived in membranes for the wild‐type receptor.
The ability to define the pH at which ligand‐binding studies are
undertaken in membrane preparations provided an opportunity to
study the influence of pH on ligand binding at the acidic pH nor-
mally found in intracellular endosomes. These data showed that
the association and dissociation rate constants of fluorescent
VEGF‐A at NanoLuc‐VEGFR2 were faster at pH 6.0 than those
observed at pH 7.4. Indeed, the parameters approached those
obtained in intact cells (Table 3). These data suggest that a propor-
tion of the ligand‐binding characteristics observed in intact cells is
a consequence of receptor endocytosis and the influence of the
lower pH environment.
In summary, the present study has shown for the first time that
NanoBRET can be used to monitor the kinetics of the binding of fluo-
rescent VEGF‐A isoforms to VEGFR2 in isolated membrane prepara-
tions. Equilibrium measurements in membranes produced binding
parameters that were of a similar order to those determined in live
cells. However, in contrast to previous studies in intact cells where
the NanoBRET signal falls towards baseline values after reaching a
peak, kinetic experiments in membranes produced classic ligand‐
binding association curves that were maintained for the duration of
the 90‐min experiment. Automated imaging allowed a quantitative
analysis of the effect of fluorescent VEGF‐A isoforms on VEGFR2
endocytosis in intact cells. These studies confirmed that all three
fluorescent ligands produced a rapid and potent translocation of
ligand‐bound VEGFR2 to intracellular endosomes.
Our data suggest that the largest impact of this rapid agonist‐
induced VEGFR2 endocytosis on ligand‐binding parameters was on
the equilibrium off‐rate kinetic constant (koff) and receptor residence
time (1/koff). Thus, rapid VEGFR2 endocytosis into intracellular
endosomes receptor in intact cells shortened the measured residence
time of VEGF165b‐TMR on the receptor from 43.5 min (in membranes)
to 12.3 min (in cells). These data suggest that the ligand‐binding kinet-
ics of VEGF‐A isoforms differ between plasma membrane and intracel-
lular endosomes and that agonist‐induced receptor endocytosis can
change both local signalling environment and ligand‐binding kinetic
properties of the receptor. These data provide important new insights
PEACH ET AL. 15BJPinto the impact of cellular location and pH on the kinetics of ligand–
receptor interactions for a receptor that is a key mediator of both
angiogenesis and vascular permeability, and an important drug target
for the treatment of cancer.
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